Andrew McMillan, Ph.D. joined 5AM Ventures in 2005 from NASA, where he was a Principal Investigator in the Bioengineering Branch and the Center for Nanotechnology at the Ames Research Center. Dr. McMillan’s research contributions in the areas of nanotech and biomaterials have resulted in five patents and nineteen publications in leading peer-reviewed journals, including Nature Materials, JACS and PNAS, and have been featured in US News & World Report, Scientific American, New Scientist, and AIChE Journal. Dr. McMillan represents 5AM working closely with the following portfolio companies: Achaogen, Ambrx, KaloBios Pharmaceuticals, Pearl Therapeutics, PhaseRx, Rennovia and Wildcat Discovery Technologies. Dr. McMillan holds a B.S. in Chemistry from UNC-Chapel Hill and a Ph.D. in Chemistry from Emory University, where he earned department honors for his research in biomaterials for drug delivery and tissue engineering. Dr. McMillan is based in the Menlo Park, CA office.